Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 3
2018 9
2019 11
2020 23
2021 26
2022 31
2023 44
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, Deniz Y, Ruddy M, Laws E, Patel N, Weinreich DM, Yancopoulos GD, Amin N, Mannent LP, Lederer DJ, Hardin M; Liberty Asthma VOYAGE Investigators. Bacharier LB, et al. N Engl J Med. 2021 Dec 9;385(24):2230-2240. doi: 10.1056/NEJMoa2106567. N Engl J Med. 2021. PMID: 34879449 Clinical Trial.
Dupilumab also resulted in significantly better asthma control than placebo (P<0.001). ...The incidence of serious adverse events was similar in the two groups. CONCLUSIONS: Among children with uncontrolled moderate-to-severe asthma, those who recei …
Dupilumab also resulted in significantly better asthma control than placebo (P<0.001). ...The incidence of serious adverse …
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
Secondary end points included the exacerbation rate and FEV(1) in patients with a blood eosinophil count of 300 or more per cubic millimeter. Asthma control and dupilumab safety were also assessed. RESULTS: The annualized rate of severe asthma exacerbations w …
Secondary end points included the exacerbation rate and FEV(1) in patients with a blood eosinophil count of 300 or more per cubic millimeter …
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Paller AS, et al. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2. Lancet. 2022. PMID: 36116481 Clinical Trial.
Dupilumab is approved for older children and adults with atopic dermatitis and for other type 2 inflammatory conditions. ...Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in older children and adults. ...
Dupilumab is approved for older children and adults with atopic dermatitis and for other type 2 inflammatory conditions. ... …
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Rabe KF, et al. N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782224 Free article. Clinical Trial.
Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining asthma control is unknown. METHODS: We randomly assigned 210 patients with oral glucocorticoid-treated asthma to receive add-on dupilumab (at a dose …
Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining asthma control is unkno …
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Hernández-Martín I, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Agache I, et al. Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24. Allergy. 2020. PMID: 32034960
Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of …
Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated th …
Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Charles D, et al. Clin Exp Allergy. 2022 May;52(5):616-627. doi: 10.1111/cea.14112. Epub 2022 Mar 9. Clin Exp Allergy. 2022. PMID: 35174566 Free PMC article. Review.
BACKGROUND: Severe asthma is a major cause of morbidity. Some patients may benefit from biological therapies. ...CONCLUSIONS: These data demonstrate that anti-IL5 biologicals may improve the clinical outcomes of patients with severe asthma in a clinic environment wi …
BACKGROUND: Severe asthma is a major cause of morbidity. Some patients may benefit from biological therapies. ...CONCLUSIONS: These d …
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Wechsler ME, et al. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. Lancet Respir Med. 2022. PMID: 34597534 Clinical Trial.
BACKGROUND: Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as dat …
BACKGROUND: Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. …
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
van Dijk YE, Rutjes NW, Golebski K, Şahin H, Hashimoto S, Maitland-van der Zee AH, Vijverberg SJH. van Dijk YE, et al. Paediatr Drugs. 2023 Nov;25(6):677-693. doi: 10.1007/s40272-023-00589-4. Epub 2023 Sep 2. Paediatr Drugs. 2023. PMID: 37658954 Free PMC article. Review.
Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. ...Biologics that are currently approved to treat children ( 6 years of age) or adolescents ( 12 years of age) with severe asthma include: anti-immun …
Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. ...Biologics that are c …
Mechanisms of Dupilumab.
Harb H, Chatila TA. Harb H, et al. Clin Exp Allergy. 2020 Jan;50(1):5-14. doi: 10.1111/cea.13491. Epub 2019 Sep 30. Clin Exp Allergy. 2020. PMID: 31505066 Free PMC article. Review.
In this review, we detail the current state of knowledge of the different signalling pathways coupled to the IL-4R complexes and examine the possible mechanisms of Dupilumab action and survey its clinical efficacy in different allergic disorders. The development of Dupi …
In this review, we detail the current state of knowledge of the different signalling pathways coupled to the IL-4R complexes and examine the …
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.
Fiocchi AG, Phipatanakul W, Zeiger RS, Durrani SR, Cole J, Msihid J, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M, Zhang Y, Khan AH. Fiocchi AG, et al. Eur Respir J. 2023 Nov 2;62(5):2300558. doi: 10.1183/13993003.00558-2023. Print 2023 Nov. Eur Respir J. 2023. PMID: 37734856 Free PMC article. Clinical Trial.
BACKGROUND: Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more detail the impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their careg …
BACKGROUND: Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more …
150 results